The Role of Concomitant Methotrexate in Biologic Therapy for Rheumatoid Arthritis

被引：0
作者：
Ruderman, Eric M. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Med, Chicago, IL 60611 USA
来源：
BULLETIN OF THE HOSPITAL FOR JOINT DISEASES | 2013年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];
学科分类号：
摘要：
From the first use of biologic therapy for the management of rheumatoid arthritis, methotrexate (MTX) has been commonly used as co-therapy. There are a number of mechanistic reasons why MTX may improve the efficacy of biologics, including reduced antigenicity as well as reduced clearance of the biologic agent. Clinical trial data for tumor necrosis factor inhibitors and for other biologic agents does suggest added efficacy when these agents are used in combination with MTX. One exception may be the interleukin-6 receptor antibody tocilizumab, for which there is some data to suggest that monotherapy may be as effective as combined therapy with MTX. Post-marketing registry data also supports the concomitant use of MTX with biologics, with evidence for greater efficacy and longer persistence on treatment when compared with monotherapy.
引用
收藏
页码：S29 / S32
页数：4
相关论文
共 19 条
[1]   Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].
Bartelds, Geertje M. ;
Wijbrandts, Carla A. ;
Nurmohamed, Michael T. ;
Stapel, Steven ;
Lems, Willem F. ;
Aarden, Lucien ;
Dijkmans, Ben A. C. ;
Tak, Paul Peter ;
Wolbink, Gerrit Jan .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926
[2]   Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review [J].
Blum, Marissa A. ;
Koo, Danielle ;
Doshi, Jalpa A. .
CLINICAL THERAPEUTICS, 2011, 33 (07) :901-913
[3]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[4]   Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].
Edwards, JCW ;
Szczepanski, L ;
Szechinski, J ;
Filipowicz-Sosnowska, A ;
Emery, P ;
Close, DR ;
Stevens, RM ;
Shaw, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581
[5]   Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry [J].
Hetland, Merete Lund ;
Christensen, Ib Jarle ;
Tarp, Ulrik ;
Dreyer, Lene ;
Hansen, Annette ;
Hansen, Ib Tonder ;
Kollerup, Gina ;
Linde, Louise ;
Lindegaard, Hanne M. ;
Poulsen, Uta Engling ;
Schlemmer, Annette ;
Jensen, Dorte Vendelbo ;
Jensen, Signe ;
Hostenkamp, Gisela ;
Ostergaard, Mikkel .
ARTHRITIS AND RHEUMATISM, 2010, 62 (01) :22-32
[6]   Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis - Results from the British Society for Rheumatology Biologics Register [J].
Hyrich, Kimme L. ;
Symmons, Deborah P. M. ;
Watson, Kath D. ;
Silman, Alan J. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (06) :1786-1794
[7]   Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors [J].
Iannone, Florenzo ;
Gremese, Elisa ;
Atzeni, Fabiola ;
Biasi, Domenico ;
Botsios, Costantino ;
Cipriani, Paola ;
Ferri, Clodoveo ;
Foschi, Valentina ;
Galeazzi, Mauro ;
Gerli, Roberto ;
Giardina, Annarita ;
Marcheson, Antonio ;
Salaffi, Fausto ;
Ziglioli, Tamara ;
Lapadula, Giovanni .
JOURNAL OF RHEUMATOLOGY, 2012, 39 (06) :1179-1184
[8]   Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study [J].
Kameda, Hideto ;
Kanbe, Katsuaki ;
Sato, Eri ;
Ueki, Yukitaka ;
Saito, Kazuyoshi ;
Nagaoka, Shouhei ;
Hidaka, Toshihiko ;
Atsumi, Tatsuya ;
Tsukano, Michishi ;
Kasama, Tsuyoshi ;
Shiozawa, Shunichi ;
Tanaka, Yoshiya ;
Yamanaka, Hisashi ;
Takeuchi, Tsutomu .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (08) :1585-1592
[9]   Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial [J].
Kameda, Hideto ;
Ueki, Yukitaka ;
Saito, Kazuyoshi ;
Nagaoka, Shouhei ;
Hidaka, Toshihiko ;
Atsumi, Tatsuya ;
Tsukano, Michishi ;
Kasama, Tsuyoshi ;
Shiozawa, Shunichi ;
Tanaka, Yoshiya ;
Takeuchi, Tsutomu .
MODERN RHEUMATOLOGY, 2010, 20 (06) :531-538
[10]   Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice [J].
Kaufmann, Joerg ;
Feist, Eugen ;
Roske, Anne-Eve ;
Schmidt, Wolfgang A. .
CLINICAL RHEUMATOLOGY, 2013, 32 (09) :1347-1355
12